The 12 closest competitors and alternatives to Nested Therapeutics among biotechnology companies — ranked by similarity to what Nested Therapeutics actually does, not by market-cap band.
Subscribe to see Nested Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nested Therapeutics is a privately held biotech company headquartered in Cambridge, Massachusetts, focused on advancing precision oncology medicine by uncovering hidden driver mutations.
Nested Therapeutics is a biotechnology company headquartered in United States. It has raised at least $125M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $90M in October 2022. Xcout tracks 15 named people at Nested Therapeutics, including Darrin Miles (Chief Executive Officer).
9 more named people on record for Nested Therapeutics, with roles, board committees and tenure — see the full roster →
At least $125M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $90M | 10 named | |
| Seed | $35M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Nested Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Similar biotechnology company
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Similar biotechnology company
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Similar biotechnology company
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Similar biotechnology company
KOMO Biosciences is a biotechnology research company headquartered in Cambridge, Massachusetts. The company specializes in next-generation precision genome engineering driven by highly efficient, evolved integrases.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Biotech
Fore Biotherapeutics is a virtual precision oncology company rooted in science and innovation, with expertise and talent across the USA. The company is focused on developing treatments, including its Plixorafenib Program.
Biotech
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Similar biotechnology company
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Nested Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →